Clinical Trial Details

Overview

Research Study Summary

Inspire® Upper Airway Stimulation System (UAS): Post-Approval Study

Purpose

The purpose of this study is to obtain additional long-term safety and efficacy data on the use of Inspire therapy.

To Learn more

CW ID: 209246
Date Last Changed: July 21, 2015

Clinical Trial Snapshot

Phase
4
Gender
Both Male and Female
Age
22 and up
Overall Status
Recruiting
Lead Sponsor
Inspire Medical Systems, Inc.
Facility Type
In-Patient

Eligibility

Inclusion Criteria:

  • Likely suffer moderate-to-severe OSA based on history and physical or have an established diagnosis of OSA (20≤AHI≤65) based on a prior in-lab Polysomnography
  • Documentation the subject not effectively treated with CPAP therapy. (Examples include non-compliance, discomfort, undesirable side effects, symptoms persist despite use). Subjects who have been prescribed, but refuse to try CPAP would be considered intolerant
  • Age 22 or above
  • Willing and capable to have stimulation hardware permanently implanted, and to use the patient remote to activate the stimulation
  • Willing and capable to return for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires
  • Willing and capable of providing informed consent

Exclusion Criteria:

Contraindications:

  • Central + mixed apneas > 25% of the total apnea-hypopnea index (AHI)
  • Any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate
  • Any condition or procedure that has compromised neurological control of the upper airway
  • Patients who are unable or do not have the necessary assistance to operate the patient remote
  • Patients who are pregnant or plan to become pregnant
  • Patients who will require magnetic resonance imaging (MRI)
  • Patients with an implantable device that may be susceptible to unintended interaction with the Inspire system

Additional exclusions for study purposes only:

  • Body Mass Index (BMI) of > 32
  • Any chronic medical illness or condition that contraindicates a surgical procedure under general anesthesia, as judged by the clinical study Investigator
  • Has a terminal illness with life expectancy < 12 months
  • Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject compliance with the requirements of the investigational study testing
  • Any other reason the investigator deems subject is unfit for participation in the study

More Info

Protocol Number: 2014-001

Detailed Description:

This is a multi-center, prospective, single-arm study conducted under a common protocol. Each subject will serve as their own control. Each subject will be followed for 5 years from date of implant.

Potential study subjects will be considered for study participation and consented once pre-implant screening and implant qualification process have been completed. This includes an in-lab PSG, surgical consultation, and a drug-induced sleep endoscopy procedure.

This study will collect pre-operative baseline data including, verification of ineffective CPAP treatment, PSG information, medical history and subject quality of life measures. Intra- and post- operative procedure data will be collected.

Post-implant, procedure- and device-related adverse events, QoL questionnaires, Functional Tongue Exam, therapy usage and device adjustment data will be collected. In-lab PSG sleep study data will be collected during the 2-month and 1 & 3 year follow-up visits, home sleep tests will be conducted and data collected at the 6-month and 2, 4, & 5 year follow-up visits.

The subject population will consists of otherwise healthy men and women that are at least 21 years old and have: 1) Provided written informed consent to participate, 2) Indicated a willingness to comply with the study requirements for the specified follow-up duration, and 3) Met all inclusion and exclusion criteria of this protocol.

Up to 127 subjects will be implanted at a minimum of 10 and a maximum of 20 qualified sites in the United States.

Contact

Laurie Joughin
University of South Florida- Tampa General Hospital
1 Tampa General Circle
Tampa, FL 33606
Phone: 813-844-8153

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.